We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

93 hedge funds and large institutions have $276M invested in Dianthus Therapeutics in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 30 increasing their positions, 24 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 24

0.04% more ownership

Funds ownership: 4% → 4.04% (+0.04%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

4% less funds holding

Funds holding: 97 → 93 (-4)

21% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 19

25% less capital invested

Capital invested by funds: $366M → $276M (-$90.3M)

Holders
93
Holders Change
-4
Holders Change %
-4.12%
% of All Funds
1.63%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
15
Increased
30
Reduced
24
Closed
19
Calls
$86K
Puts
–
Net Calls
+$86K
Net Calls Change
+$85K

Top Buyers

Rank Fund Capital Flow
1
CC
Casdin Capital
New York
+$4.05M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$3.99M
3
WP
Woodline Partners
California
+$3.75M
4
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$3.51M
5
ACM
Aquilo Capital Management
California
+$3.41M

Top Sellers

Rank Fund Capital Flow
1
TGI
TRV GP IV
Massachusetts
-$9.1M
2
EC
EcoR1 Capital
California
-$3.59M
3
GGHC
Gilder Gagnon Howe & Co
New York
-$2.42M
4
O
OrbiMed
New York
-$1.03M
5
Citadel Advisors
Citadel Advisors
Florida
-$1.01M
Name Holding Trade Value Shares
Change 		Change in
Stake
Rockefeller Capital Management
76
Rockefeller Capital Management
New York
$26K +$26.2K +225 New
Legal & General Group
77
Legal & General Group
United Kingdom
$22K – – –
Russell Investments Group
78
Russell Investments Group
United Kingdom
$15K -$30.2K -259 -66%
SIAP
79
Sterling Investment Advisors (Pennsylvania)
Pennsylvania
$15K – – –
AIP
80
Ameritas Investment Partners
Nebraska
$13K – – –
TRCT
81
Tower Research Capital (TRC)
New York
$10K -$62.7K -538 -86%
SOW
82
State of Wyoming
Wyoming
$10K +$1.98K +17 +23%
BDWM
83
Brewin Dolphin Wealth Management
Ireland
$9.46K – – –
PCM
84
Penserra Capital Management
California
$9K – – –
SO
85
STRS Ohio
Ohio
$8K – – –
Daiwa Securities Group
86
Daiwa Securities Group
Japan
$1K – – –
FF
87
FourThought Financial
Florida
$1K – – –
HR
88
Howe & Rusling
New York
$1K +$233 +2 +50%
S
89
SignatureFD
Georgia
$1K +$583 +5 New
Osaic Holdings
90
Osaic Holdings
Arizona
$1K +$932 +8 New
Nisa Investment Advisors
91
Nisa Investment Advisors
Missouri
$112 +$112K +962 New
EC
92
EcoR1 Capital
California
– -$3.59M -22,929 Closed
Citadel Advisors
93
Citadel Advisors
Florida
– -$1.01M -8,642 Closed
SCM
94
Soleus Capital Management
Connecticut
– -$880K -5,625 Closed
DCM
95
Driehaus Capital Management
Illinois
– -$782K -5,000 Closed
Millennium Management
96
Millennium Management
New York
– -$627K -4,007 Closed
SFI
97
Susquehanna Fundamental Investments
Pennsylvania
– -$488K -3,121 Closed
Squarepoint
98
Squarepoint
New York
– -$328K -2,098 Closed
PP
99
PDT Partners
New York
– -$246K -1,575 Closed
JF
100
Jump Financial
Illinois
– -$230K -1,469 Closed
1 2 3
4
5

DNTH Hedge Fund Activity: Q3 2021 in Review

93 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q3 2021, worth a combined $276M — down 25% from $366M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of DNTH and 15 opened new positions — a net loss of 4 holders — while 24 trimmed existing stakes and 30 added.

The largest buyer was Casdin Capital, adding an estimated $4.05M. The largest seller was TRV GP IV, cutting an estimated $9.1M.

  • 93 institutional investors held Dianthus Therapeutics (DNTH) as of Q3 2021, down from 97 in Q2 2021.
  • Funds reported $276M of Dianthus Therapeutics stock for Q3 2021, down 25% quarter-over-quarter.
  • 15 funds opened new Dianthus Therapeutics positions in Q3 2021 and 19 closed out, a net change of -4 holders.
  • The largest Dianthus Therapeutics buyer in Q3 2021 was Casdin Capital, an estimated $4.05M added.
  • The largest Dianthus Therapeutics seller in Q3 2021 was TRV GP IV, an estimated $9.1M sold.

Based on aggregated 13F filings for Q3 2021.